Notice of General Meeting

Summary by AI ^BETAClose X

CRISM Therapeutics Corporation has announced a General Meeting to be held on Monday, June 15, 2026, at 10:00 a.m. This meeting follows the Company's Fundraising announcement on May 26, 2026, and further details will be posted to shareholders. The company is a UK clinical-stage drug delivery firm focused on localized and sustained chemotherapy delivery for solid tumors, with its lead product, ChemoSeed, designed for direct implantation into tumors or resection margins.

Disclaimer*

CRISM Therapeutics Corporation

27 May 2026

CRISM Therapeutics Corporation

("CRISM", "CRISM Therapeutics" or the "Company")

Notice of General Meeting

CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that, following the Company's Fundraising announcement of 26 May 2026, the General Meeting will take place at 10.00 a.m. on Monday 15 June 2026 at the offices of Fieldfisher LLP, Riverbank House, 2 Swan Lane, London, EC4R 3TT. Further details are set out in the Notice of General Meeting, which will be posted to Shareholders today.

A copy of the Notice of General Meeting will shortly be available on the Company's website at: https://www.crismtherapeutics.com/investors/documents-circulars/

Capitalised terms not defined shall have the same meaning as given to them in the Company's announcement of 26 May 2026.

-Ends-

Enquiries:

Company	Nomad and Broker	Financial PR
CRISM Therapeutics Corporation	S.P. Angel Corporate Finance LLP	Burson Buchanan
Andrew Webb, Executive Chairman Chris McConville, CSO	David Hignell Vadim Alexandre Adam Cowl	Henry Harrison Topham Jamie Hooper CRISM@buchanancomms.co.uk
via Burson Buchanan	+44 (0) 20 3470 0470	+44 (0) 20 7466 5000

About CRISM Therapeutics Corporation

CRISM Therapeutics Corporation has developed an innovative drug delivery technology to improve the clinical performance of cancer treatments for solid tumours through the local delivery of chemotherapy drugs.

ChemoSeed, CRISM's lead product, can be implanted directly into the tumour or the resection margin following the removal of a tumour. This directs that therapeutic concentrations of chemotherapy drugs reach the deep-seated tumour tissue or cover the entire resection margin. In the case of treating glioblastoma, ChemoSeeds can be implanted during surgery thereby bypassing the blood brain barrier, which prevents other treatments from being able to reach the tumour and be effective.

For more information please visit: https://www.crismtherapeutics.com/

The Company's LEI is 213800XFW6MKVCHHPW88.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END